

# Keith G Oldroyd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6148379/publications.pdf>

Version: 2024-02-01

234  
papers

26,629  
citations

13865

67  
h-index

6131

159  
g-index

239  
all docs

239  
docs citations

239  
times ranked

14298  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2009, 360, 213-224.	27.0	3,510
2	Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2012, 367, 991-1001.	27.0	2,248
3	Angiographic Versus Functional Severity of Coronary Artery Stenoses in the FAME Study. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2816-2821.	2.8	1,077
4	Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 177-184.	2.8	990
5	Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2014, 371, 1208-1217.	27.0	905
6	Randomized Trial of Preventive Angioplasty in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2013, 369, 1115-1123.	27.0	871
7	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2017, 377, 2419-2432.	27.0	764
8	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	27.0	683
9	Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2015, 373, 2038-2047.	27.0	672
10	Smoke-free Legislation and Hospitalizations for Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2008, 359, 482-491.	27.0	640
11	Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. <i>New England Journal of Medicine</i> , 2018, 379, 250-259.	27.0	622
12	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. <i>Lancet</i> , The, 2016, 388, 2743-2752.	13.7	620
13	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , The, 2018, 392, 940-949.	13.7	555
14	Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions. <i>Circulation</i> , 2010, 121, 1235-1243.	1.6	478
15	Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 1853-1860.	13.7	455
16	Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2005, 353, 2758-2768.	27.0	436
17	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2841-2855.	2.8	436
18	Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2010, 55, 432-440.	2.8	421

#	ARTICLE	IF	CITATIONS
19	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. <i>Lancet, The</i> , 2019, 394, 1325-1334.	13.7	406
20	Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2013, 127, 2436-2441.	1.6	316
21	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2018, 379, 1699-1710.	27.0	303
22	Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting P <sub>1</sub> /P <sub>2</sub> With Fractional Flow Reserve. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1253-1261.	2.8	301
23	Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. <i>Lancet, The</i> , 2020, 395, 191-199.	13.7	280
24	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , 2015, 36, 100-111.	2.2	241
25	Adenosine. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 581-591.	2.9	214
26	Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 248-255.	3.9	205
27	A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI). <i>Journal of the American College of Cardiology</i> , 2014, 63, 2088-2098.	2.8	204
28	Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 222-226.	2.2	197
29	VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment) Tj ETQq1 1 0.784314 rgBT /Ove Cardiology, 2013, 61, 1421-1427.	2.8	197
30	Validation of Magnetic Resonance Myocardial Perfusion Imaging With Fractional Flow Reserve for the Detection of Significant Coronary Heart Disease. <i>Circulation</i> , 2009, 120, 2207-2213.	1.6	191
31	Primary Endpoint Results of the EVOLVE Trial. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1362-1370.	2.8	188
32	Fractional Flow Reserveâ€“Guided PCI as Compared with Coronary Bypass Surgery. <i>New England Journal of Medicine</i> , 2022, 386, 128-137.	27.0	169
33	Comparison of Different Diastolic RestingÂIndexes to iFR. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3088-3096.	2.8	163
34	The Index of Microcirculatory Resistance Measured Acutely Predicts the Extent and Severity of Myocardial Infarction in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 715-722.	2.9	161
35	Myocardial Hemorrhage After Acute Reperfused ST-Segmentâ€“Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004148.	2.6	158
36	Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. <i>EuroIntervention</i> , 2018, 14, 806-814.	3.2	157

#	ARTICLE	IF	CITATIONS
37	Simple or Complex Stenting for Bifurcation Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 57-64.	3.9	152
38	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 33-45.	2.9	141
39	Systemic microvascular dysfunction in microvascular and vasospastic angina. <i>European Heart Journal</i> , 2018, 39, 4086-4097.	2.2	139
40	Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1833-1847.	1.6	135
41	Continuum of Vasodilator Stress Fromâ€Rest to Contrast Medium toâ€Adenosine Hyperemia for Fractionalâ€Flow Reserve Assessment. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 757-767.	2.9	129
42	Validation of coronary flow reserve measurements by thermodilution in clinical practice. <i>European Heart Journal</i> , 2004, 25, 219-223.	2.2	128
43	Ticagrelor With or Without Aspirin After Complexâ€PCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	2.8	122
44	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. <i>Circulation</i> , 2021, 144, 1476-1484.	1.6	121
45	Importance of collateral circulation in coronary heart disease. <i>European Heart Journal</i> , 2007, 28, 278-291.	2.2	118
46	Pathophysiology of LV Remodeling inâ€Survivors of STEMI. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 779-789.	5.3	116
47	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1130.	6.1	114
48	The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). <i>European Heart Journal</i> , 2007, 28, 433-442.	2.2	113
49	Ischemia and No Obstructive Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008126.	3.9	107
50	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. <i>European Heart Journal</i> , 2016, 37, 1044-1059.	2.2	105
51	Vasodilatory Capacity of the Coronary Microcirculation is Preserved in Selected Patients With Nonâ€ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 231-236.	3.9	103
52	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. <i>European Heart Journal</i> , 2016, 37, 1923-1928.	2.2	103
53	The EBC TWO Study (European Bifurcation Coronary TWO). <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	102
54	Bright-Blood T2-Weighted MRI Has Higher Diagnostic Accuracy Than Dark-Blood Short Tau Inversion Recovery MRI for Detection of Acute Myocardial Infarction and for Assessment of the Ischemic Area at Risk and Myocardial Salvage. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 210-219.	2.6	99

#	ARTICLE	IF	CITATIONS
55	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute STâ€Segment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. Journal of the American Heart Association, 2016, 5, .	3.7	96
56	Reducing In-Stent Restenosis. Journal of the American College of Cardiology, 2015, 65, 2314-2327.	2.8	95
57	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 2016, 172, 160-169.	2.7	93
58	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
59	Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. American Journal of Cardiology, 1991, 68, 713-718.	1.6	90
60	Integrated Physiologic Assessment of Ischemic Heart Disease in Real-World Practice Using Index of Microcirculatory Resistance and Fractional Flow Reserve. Circulation: Cardiovascular Interventions, 2015, 8, e002857.	3.9	89
61	Prognostic Value and Risk Continuum of Noninvasive Fractional Flow Reserve Derived from Coronary CT Angiography. Radiology, 2019, 292, 343-351.	7.3	89
62	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 56.	7.4	88
63	Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology. Catheterization and Cardiovascular Interventions, 2008, 71, 198-204.	1.7	87
64	Repeatability of Fractional Flow Reserve Despite Variations in Systemic andâ€Coronaryâ€Hemodynamics. JACC: Cardiovascular Interventions, 2015, 8, 1018-1027.	2.9	83
65	The Influence of Lesion Location on the Diagnostic Accuracy of Adenosine-Free Coronary Pressure Wire Measurements. JACC: Cardiovascular Interventions, 2016, 9, 2390-2399.	2.9	81
66	Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2012, 1, e002246.	3.7	80
67	Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). European Heart Journal, 2021, 42, 4656-4668.	2.2	79
68	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal, 2020, 41, 3239-3252.	2.2	73
69	Intravascular Imaging and 12-Month Mortality After Unprotected Left Main Stemâ€PCI. JACC: Cardiovascular Interventions, 2020, 13, 346-357.	2.9	70
70	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	67
71	Impact of left ventricular function in relation to procedural outcomes following percutaneous coronary intervention: insights from the British Cardiovascular Intervention Society. European Heart Journal, 2014, 35, 3004-3012.	2.2	65
72	Percutaneous Coronary Intervention in the Elderly. Circulation: Cardiovascular Interventions, 2010, 3, 341-345.	3.9	63

#	ARTICLE	IF	CITATIONS
73	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	2.8	60
74	Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. <i>European Heart Journal</i> , 2015, 36, 3155-3164.	2.2	58
75	Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. <i>American Heart Journal</i> , 2015, 170, 619-626.e2.	2.7	58
76	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	2.2	54
77	Radial versus femoral approach for high-speed rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 550-554.	1.7	53
78	Single Versus 2 Stent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis of Randomized Trials With Long-Term Follow-up. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	53
79	Accuracy of Fractional Flow Reserve Measurements in Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1392-1401.	2.9	49
80	Predictive factors of discordance between the instantaneous wave-free ratio and fractional flow reserve. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 356-363.	1.7	49
81	Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 993-1003.	5.3	46
82	Validity of self-reported smoking status: Comparison of patients admitted to hospital with acute coronary syndrome and the general population. <i>Nicotine and Tobacco Research</i> , 2008, 10, 861-866.	2.6	45
83	Clinical outcomes following radial versus femoral artery access in primary or rescue percutaneous coronary intervention in Scotland: retrospective cohort study of 4534 patients. <i>Heart</i> , 2012, 98, 552-557.	2.9	45
84	Fractional flow reserve derived from coronary CT angiography: Variation of repeated analyses. <i>Journal of Cardiovascular Computed Tomography</i> , 2014, 8, 307-314.	1.3	45
85	Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. <i>Hypertension</i> , 2016, 68, 385-391.	2.7	44
86	Diastolic pressure ratio: new approach and validation vs. the instantaneous wave-free ratio. <i>European Heart Journal</i> , 2019, 40, 2585-2594.	2.2	44
87	Agreement of the Resting Distal to Aortic Coronary Pressure With the Instantaneous Wave-Free Ratio. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2105-2113.	2.8	43
88	Persistent Iron Within the Infarct Core After ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1248-1256.	5.3	43
89	Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study. <i>International Journal of Cardiology</i> , 2018, 266, 7-14.	1.7	41
90	Influence of access site choice for cardiac catheterization on risk of adverse neurological events: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2016, 181, 107-119.	2.7	40

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1321-1329.	2.8	40
92	Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. <i>JCI Insight</i> , 2016, 1, e85768.	5.0	39
93	Three-Year Results Comparing Platinum-Chromium PROMUS Element and Cobalt-Chromium XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Narrowing (from the PLATINUM Trial). <i>American Journal of Cardiology</i> , 2014, 113, 1117-1123.	1.6	37
94	Comparative Significance of Invasive Measures of Microvascular Injury in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008505.	3.9	37
95	Outcomes in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial). <i>American Journal of Cardiology</i> , 2014, 113, 1457-1460.	1.6	35
96	Comparison of Characteristics and Complications in Men Versus Women Undergoing Chronic Total Occlusion Percutaneous Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 535-541.	1.6	35
97	Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. <i>Hypertension</i> , 2018, 72, 720-730.	2.7	33
98	Evaluation and Management of Nonculprit Lesions in STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1145-1154.	2.9	33
99	Meta-Analysis of Death and Myocardial Infarction in the DEFINE-FLAIR and iFR-SWEDEHEART Trials. <i>Circulation</i> , 2017, 136, 2389-2391.	1.6	32
100	Circumferential Strain Predicts Major Adverse Cardiovascular Events Following an Acute ST-Segment Elevation Myocardial Infarction. <i>Radiology</i> , 2019, 290, 329-337.	7.3	32
101	Fractional Flow Reserve-Based Coronary Artery Bypass Surgery. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1086-1096.	2.9	32
102	The Role of Cardiac Magnetic Resonance Imaging (MRI) in Acute Myocardial Infarction (AMI). <i>Heart Lung and Circulation</i> , 2013, 22, 243-255.	0.4	31
103	Comprehensive Dobutamine Stress CMR Versus Echocardiography in LBBB and Suspected Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 490-498.	5.3	30
104	Combining mathematical modelling with in vitro experiments to predict in vivo drug-eluting stent performance. <i>Journal of Controlled Release</i> , 2019, 303, 151-161.	9.9	28
105	Fractional flow reserve and the index of microvascular resistance in patients with acute coronary syndromes. <i>EuroIntervention</i> , 2014, 10, T55-T63.	3.2	28
106	Microvascular (Dys)Function and Clinical Outcome in Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1170-1172.	2.8	27
107	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study. <i>American Heart Journal</i> , 2020, 221, 48-59.	2.7	27
108	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	2.9	27

#	ARTICLE	IF	CITATIONS
109	The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease. <i>Thrombosis Research</i> , 2012, 130, 210-215.	1.7	25
110	Prevention of coronary in-stent restenosis and vein graft failure: Does vascular gene therapy have a role?. , 2012, 136, 23-34.		25
111	The Potential Use of the Index of Microcirculatory Resistance to Guide Stratification of Patients for Adjunctive Therapy in Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 951-966.	2.9	25
112	Low serum cortisol predicts early death after acute myocardial infarction. <i>Critical Care Medicine</i> , 2010, 38, 973-975.	0.9	24
113	Sex differences in procedural and clinical outcomes following rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 232-241.	1.7	24
114	Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segmentâ€Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009937.	2.6	24
115	Outcomes of Percutaneous Coronary Intervention Performed at Offsite Versusâ€Onsite Surgical Centers inâ€Theâ€United Kingdom. <i>Journal of the American College of Cardiology</i> , 2015, 66, 363-372.	2.8	22
116	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. <i>American Heart Journal</i> , 2018, 201, 86-94.	2.7	22
117	Usefulness of Fractional Flow Reserve to Improve Diagnostic Efficiency in Patients With Non-ST Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2013, 111, 45-50.	1.6	21
118	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 12-19.	0.5	20
119	Urine proteomics in the diagnosis of stable angina. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 70.	1.7	20
120	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 202, 305-310.	1.7	20
121	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	1.7	19
122	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	2.2	18
123	Assessment of Fractional Flow Reserve in Patients With Recent Nonâ€ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002207.	3.9	17
124	Intravascular ultrasound assessment of the effects of rotational atherectomy in calcified coronary artery lesions. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1365-1371.	1.5	17
125	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007830.	3.9	17
126	Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II). <i>EuroIntervention</i> , 2009, 5, 190-196.	3.2	17



#	ARTICLE	IF	CITATIONS
127	Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 45-52.	3.9	16
128	Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug) Trial. <i>Overlook 10 Tf 5</i> 410-417.	2.1	16
129	Persistence of Infarct Zone T2 Hyperintensity at 6 Months After Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	16
130	Predictors of segmental myocardial functional recovery in patients after an acute ST-Elevation myocardial infarction. <i>European Journal of Radiology</i> , 2019, 112, 121-129.	2.6	16
131	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1406-1421.	2.8	16
132	Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC Bifurcation Study. <i>EuroIntervention</i> , 2018, 14, e318-e324.	3.2	16
133	Pro-healing drug-eluting stents: a role for antioxidants?. <i>Clinical Science</i> , 2008, 114, 265-273.	4.3	15
134	Myocardial Repair and Regeneration: Bone Marrow or Cardiac Stem Cells?. <i>Molecular Therapy</i> , 2012, 20, 1102-1105.	8.2	15
135	Quality of life following percutaneous coronary interventions in octogenarians: a systematic review. <i>Heart</i> , 2013, 99, 779-784.	2.9	15
136	Diagnostic Accuracy of 3.0-T Magnetic Resonance T1 and T2 Mapping and T2-Weighted Dark-Blood Imaging for the Infarct-Related Coronary Artery in Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	15
137	Safety of Selective Intracoronary Hypothermia During Primary Percutaneous Coronary Intervention in Patients With Anterior STEMI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2047-2055.	2.9	15
138	Drug-eluting stents: A study of international practice. <i>American Heart Journal</i> , 2009, 158, 576-584.	2.7	14
139	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 19.	1.5	14
140	Radial Versus Femoral Access for Rotational Atherectomy. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	14
141	Outcomes following implantation of the biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the BIOSEARCH-2 registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1151-1160.	1.7	13
142	A randomized controlled trial of a physiology-guided percutaneous coronary intervention optimization strategy: Rationale and design of the TARGET FFR study. <i>Clinical Cardiology</i> , 2020, 43, 414-422.	1.8	13
143	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. <i>Heart</i> , 2020, 106, 758-764.	2.9	13
144	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1434-1446.	2.9	13

#	ARTICLE	IF	CITATIONS
145	Use of troponin to diagnose periprocedural myocardial infarction: effect on composite endpoints in the British Bifurcation Coronary Study (BBC ONE). <i>Heart</i> , 2012, 98, 1431-1435.	2.9	12
146	Succinobucolâ€œeluting stents increase neointimal thickening and periâ€œstrut inflammation in a porcine coronary model. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 698-708.	1.7	12
147	Invasive assessment of the coronary microcirculation in the catheter laboratory. <i>International Journal of Cardiology</i> , 2015, 199, 141-149.	1.7	12
148	The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. <i>Open Heart</i> , 2016, 3, e000342.	2.3	12
149	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. <i>Open Heart</i> , 2018, 5, e000924.	2.3	12
150	Access Site and Outcomes for Unprotected Left Main Stem Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2480-2491.	2.9	12
151	Sex Differences in Adenosine-Free Coronary Pressure Indexes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1454-1463.	2.9	12
152	Fractional flow reserve versus angiography in guiding management to optimize outcomes in nonâ€œST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial. <i>American Heart Journal</i> , 2013, 166, 662-668.e3.	2.7	11
153	Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention. <i>Heart</i> , 2016, 102, 1980-1987.	2.9	11
154	Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. <i>American Heart Journal</i> , 2017, 187, 104-111.	2.7	11
155	Safety and Efficacy of Polymer-Free Biolimus A9â€œCoated Versus Bare-Metal Stents in Orally Anticoagulated Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1633-1642.	2.9	11
156	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014066.	3.7	11
157	Comparison of risk prediction models in infarct-related cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 890-897.	1.0	11
158	Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. <i>Journal of Public Health</i> , 2008, 30, 186-193.	1.8	10
159	Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 40, 1508-14.	1.4	10
160	Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. <i>Platelets</i> , 2015, 26, 17-24.	2.3	10
161	A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserveâ€œguided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. <i>American Heart Journal</i> . 2019. 214. 156-157.	2.7	10
162	Free radical activity during percutaneous trans-luminal coronary angioplasty. <i>Biochemical Society Transactions</i> , 1990, 18, 1183-1184.	3.4	9

#	ARTICLE	IF	CITATIONS
163	Instantaneous Wave-Free Ratio or Fractional Flow Reserve Without Hyperemia. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1916-1917.	2.8	9
164	Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study. <i>EuroIntervention</i> , 2015, 10, 1402-1408.	3.2	9
165	The Impact of Coronary Bifurcation Stenting Strategy on Health-Related Functional Status. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 139-145.	2.9	8
166	Influence of Contrast Media Dose and Osmolality on the Diagnostic Performance of Contrast Fractional Flow Reserve. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	8
167	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 860.	2.4	8
168	Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009529.	3.9	8
169	A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 431-440.	5.3	8
170	Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. <i>EuroIntervention</i> , 2022, 17, 1467-1476.	3.2	8
171	A clinical and in vitro study on the possible interaction of intravenous nitrates with heparin anticoagulation. <i>Clinical Cardiology</i> , 1994, 17, 658-661.	1.8	7
172	Drug-eluting stents: do the risks really outweigh the benefits?. <i>Heart</i> , 2008, 94, 127-128.	2.9	7
173	CMR versus SPECT for diagnosis of coronary heart disease. <i>Lancet, The</i> , 2012, 379, 2145.	13.7	7
174	Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. <i>Open Heart</i> , 2019, 6, e000979.	2.3	7
175	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	3.0	7
176	Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. <i>Platelets</i> , 2022, 33, 141-146.	2.3	7
177	Pacing termination of spontaneous ventricular tachycardia in the coronary care unit. <i>International Journal of Cardiology</i> , 1992, 36, 223-226.	1.7	6
178	Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone. <i>Cardiovascular Research</i> , 1993, 27, 296-303.	3.8	6
179	Complete Immediate Revascularization of the Patient With ST-Segmentâ€Elevation Myocardial Infarction Is the New Standard of Care. <i>Circulation</i> , 2017, 135, 1571-1573.	1.6	6
180	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	1.7	6

#	ARTICLE	IF	CITATIONS
181	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. <i>Heart</i> , 2021, 107, 299-312.	2.9	6
182	Do we really understand how drug eluted from stents modulates arterial healing?. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120575.	5.2	6
183	Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. <i>Cardiovascular Research</i> , 2022, 118, 1535-1547.	3.8	6
184	Thermodilution-derived temperature recovery time: a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. <i>EuroIntervention</i> , 2021, 17, 220-228.	3.2	6
185	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.	2.9	6
186	Quality of Life After Fractional Flow Reserve-Guided PCI Compared With Coronary Bypass Surgery. <i>Circulation</i> , 2022, 145, 1655-1662.	1.6	6
187	Waves of Edema Seem Implausible. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1868-1869.	2.8	5
188	Coronary Thermodilution Waveforms After Acute Reperfused ST-Segment Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognosis. <i>Journal of the American Heart Association</i> , 2018, 7, e008957.	3.7	5
189	One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008855.	3.9	5
190	High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study. <i>EuroIntervention</i> , 2015, 10, 1187-1194.	3.2	5
191	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	3.2	5
192	The rise and fall of drug-eluting stents: Time trend analysis in 13647 consecutive patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2007, 154, e37.	2.7	4
193	Bare-Metal versus Drug-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2008, 358, 2516-2518.	27.0	4
194	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. <i>European Journal of Health Economics</i> , 2020, 21, 1197-1209.	2.8	4
195	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs. Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.8	4
196	Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes. <i>Journal of Interventional Cardiology</i> , 2021, 2021, 1-7.	1.2	4
197	Continuous intracoronary versus standard intravenous infusion of adenosine for fractional flow reserve assessment: the HYPEREMIC trial. <i>EuroIntervention</i> , 2020, 16, 560-567.	3.2	4
198	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	3.7	4

#	ARTICLE	IF	CITATIONS
199	Elective percutaneous coronary intervention in the elderly patient. <i>Aging Health</i> , 2011, 7, 271-281.	0.3	3
200	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. <i>Biomarkers in Medicine</i> , 2011, 5, 9-30.	1.4	3
201	Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. <i>Thrombosis Research</i> , 2015, 135, 1140-1146.	1.7	3
202	Validation of the "oesmart" minimum FFR Algorithm in an unselected all comer population of patients with intermediate coronary stenoses. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 991-997.	1.5	3
203	Revascularisation and mechanical circulatory support in patients with ischaemic cardiogenic shock. <i>Heart</i> , 2019, 105, 1364-1374.	2.9	3
204	MINOCA: Requirement for Definitive Diagnostic Work-Up. <i>Heart Lung and Circulation</i> , 2019, 28, e4-e6.	0.4	3
205	Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2015, 11, 361-363.	3.2	3
206	A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI. <i>International Journal of Cardiology</i> , 2022, 347, 1-7.	1.7	3
207	Dissecting aneurysm of a right-sided descending aorta with a left-sided aortic arch. <i>International Journal of Cardiology</i> , 1988, 18, 271-274.	1.7	2
208	The RITA 3 trial. <i>Lancet</i> , The, 2002, 360, 1974.	13.7	2
209	Physiological assessment of coronary lesion severity. <i>Coronary Artery Disease</i> , 2015, 26, e8-e14.	0.7	2
210	Is Delayed Stenting of the Culprit Artery in Patients With STEMI Ever Worth the Wait? —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2805-2807.	2.8	2
211	Arterial Access for Invasive Coronary Angiography: The "Left Backhand"™. <i>Heart Lung and Circulation</i> , 2018, 27, e98-e99.	0.4	2
212	Safety and efficacy of Everolimus-eluting bioabsorbable Polymer-Coated stent in patients with long coronary lesions: The EVOLVE 48 study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	1.7	2
213	Distal Transradial (Snuffbox) Access for Coronary Catheterization: A Systematic Review. <i>Cardiology in Review</i> , 2021, 29, 210-216.	1.4	2
214	A novel algorithm for the computation of the diastolic pressure ratio in the invasive assessment of the functional significance of coronary artery disease. <i>Panminerva Medica</i> , 2021, 63, 206-213.	0.8	2
215	Meta-Analysis of the Index of Microvascular Resistance in Acute STEMI Using Incomplete Data. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 421-422.	2.9	1
216	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. <i>BMJ Open</i> , 2017, 7, e014849.	1.9	1

#	ARTICLE	IF	CITATIONS
217	Flow, pressure, anatomy: an eternal golden braid. <i>Cardiovascular Research</i> , 2021, 117, 1426-1427.	3.8	1
218	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRITâ€”SHOCK Substudy. <i>Journal of the American Heart Association</i> , 2021, 10, e021150.	3.7	1
219	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM â€” CORRIGENDUM. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 112-112.	0.5	0
220	Response to Letter Regarding Article, â€œPrognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Interventionâ€. <i>Circulation</i> , 2014, 129, e342.	1.6	0
221	Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome â€” a prospective audit. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1176-1184.	2.4	0
222	110â€”Infarct Burden Following Multivessel PCI Vs. Infarct-Only PCI in Patients with Acute Stemi: The Glasgow Prami CMR Sub-Study: Abstract 110 Table 1. <i>Heart</i> , 2015, 101, A63.1-A63.	2.9	0
223	Current frontiers in the clinical research of coronary physiology. <i>Interventional Cardiology</i> , 2015, 7, 97-108.	0.0	0
224	115â€”Persistence of Infarct Zone Oedema at 6 Months after Acute ST-elevation Myocardial Infarction: Incidence, Pathophysiology and Association with Left Ventricular Remodelling. <i>Heart</i> , 2016, 102, A81.2-A81.	2.9	0
225	133â€”Although CT Coronary Angiography in the West of Scotland is Used in a Higher Risk Population than Recommended by Nice, The Rate of Subsequent Invasive Coronary Angiography is Lower than in the Promise and Scot-Heart Studies. <i>Heart</i> , 2016, 102, A95-A95.	2.9	0
226	114â€”Persistence of Haemoglobin Degradation Products within Infarct Scar Tissue after ST-elevation Myocardial Infarction: Incidence, Correlates and Implications for Left Ventricular Remodelling. <i>Heart</i> , 2016, 102, A81.1-A81.	2.9	0
227	2â€”Coronary flow reserve and index of microvascular resistance in acute stemi. <i>Heart</i> , 2016, 102, A1.2-A1.	2.9	0
228	Time is still muscle and there is still room for improvement. <i>Heart</i> , 2017, 103, 96-97.	2.9	0
229	5â€”Effect of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease. , 2018, , .		0
230	1â€”Coronary microvascular dysfunction in stable coronary artery disease: the CE-MARC 2 coronary physiology sub-study. , 2018, , .		0
231	50â€”Ischaemia and No Obstructive Coronary Artery Disease (INOCA): prevalence and predictors of coronary vasomotion disorders. , 2019, , .		0
232	Is Hyperaemia Essential for Accurate Functional Assessment of Coronary Stenosis Severity?. <i>Interventional Cardiology Review</i> , 2015, 10, 72.	1.6	0
233	Ischaemic Heart Disease. , 2019, , 355-363.		0
234	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-86.	0.7	0